BidaskClub Downgrades Intercept Pharmaceuticals (ICPT) to Buy
BidaskClub lowered shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a strong-buy rating to a buy rating in a research report released on Saturday.
Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Intercept Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, August 7th. Needham & Company LLC restated a hold rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 2nd. Oppenheimer set a $100.00 price objective on shares of Intercept Pharmaceuticals and gave the stock a hold rating in a report on Thursday, August 2nd. Wedbush boosted their price objective on shares of Intercept Pharmaceuticals from $203.00 to $217.00 and gave the stock an outperform rating in a report on Monday, August 6th. Finally, Royal Bank of Canada lowered shares of Intercept Pharmaceuticals from an outperform rating to a sector perform rating and set a $244.00 price objective for the company. in a report on Wednesday, August 15th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals has an average rating of Buy and a consensus target price of $130.57.
Shares of NASDAQ ICPT opened at $117.65 on Friday. Intercept Pharmaceuticals has a twelve month low of $51.05 and a twelve month high of $124.40. The company has a market capitalization of $3.38 billion, a P/E ratio of -8.18 and a beta of -1.73. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 2.48.
In other Intercept Pharmaceuticals news, insider David Shapiro sold 4,917 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $111.43, for a total value of $547,901.31. Following the completion of the sale, the insider now owns 42,196 shares of the company’s stock, valued at approximately $4,701,900.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.90% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Northern Trust Corp grew its position in Intercept Pharmaceuticals by 190.3% in the 2nd quarter. Northern Trust Corp now owns 257,755 shares of the biopharmaceutical company’s stock worth $21,629,000 after purchasing an additional 168,955 shares during the period. FMR LLC grew its position in Intercept Pharmaceuticals by 17.5% in the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock worth $372,336,000 after purchasing an additional 661,542 shares during the period. Bank of New York Mellon Corp grew its position in Intercept Pharmaceuticals by 25.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 89,885 shares of the biopharmaceutical company’s stock worth $7,542,000 after purchasing an additional 18,340 shares during the period. MetLife Investment Advisors LLC bought a new stake in Intercept Pharmaceuticals in the 2nd quarter worth approximately $852,000. Finally, Metropolitan Life Insurance Co. NY grew its position in Intercept Pharmaceuticals by 436.7% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,170 shares of the biopharmaceutical company’s stock worth $602,000 after purchasing an additional 5,834 shares during the period. 69.38% of the stock is owned by institutional investors and hedge funds.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Further Reading: Book Value Per Share – BVPS
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.